Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer

Genes and Cancer

Volumn 4, Issue 11-12, 2013, Pages 535-545

  Muhlbradt, Erin ^a   Ma, Jing ^b   Severi, Gianluca ^c,d   Ortner, Elizabeth ^a   Hayes, Vanessa ^e   Hoang, Hoa N ^c,d   Stampfer, Meir ^b   Giles, Graham ^c,d   Pollak, Michael ^f   Gelmann, Edward P ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

IGF 1; IGFBP 3; NKX3.1; prostate cancer

Indexed keywords

PROTEIN VARIANT; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ANDROGEN REGULATED HOMEOBOX GENE; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CASE CONTROL STUDY; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; GENOTYPE; HUMAN; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 84891515443     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913506009     Document Type: Article

References (39)

1. Swalwell JI,Vocke CD,Yang Y, et al.Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer. 2002;33 (2): 201-5.
2. Bowen C,Bubendorf L,Voeller HJ, et al.Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.Cancer Res. 2000;60 (21): 6111-5.
3. Asatiani E,Huang WX,Wang A, et al.Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.Cancer Res. 2005;65 (4): 1164-73.
4. Bhatia-Gaur R,Donjacour AA,Sciavolino PJ, et al.Roles for Nkx3.1 in prostate development and cancer.Genes Dev. 1999;13:966-77.
5. Kim MJ,Cardiff RD,Desai N, et al.Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.Proc Natl Acad Sci U S A. 2002;99 (5): 2884-9.
6. Bethel CR,Faith D,Li X, et al.Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion.Cancer Res. 2006;66 (22): 10683-90.
7. Markowski MC,Bowen C,Gelmann EP.Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1.Cancer Res. 2008;68 (17): 6896-901.
8. Voeller HJ,Augustus M,Madlike V,Bova GS,Carter KC,Gelmann EP.Coding region of NKX3.1, prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers.Cancer Res. 1997;57:4455-9.
9. Zheng SL,Ju JH,Chang BL, et al.Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function.Cancer Res. 2006;66 (1): 69-77.
10. Khandwala HM,McCutcheon IE,Flyvbjerg A,Friend KE.The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.Endocr Rev. 2000;21 (3): 215-44.
11. Jones JI,Clemmons DR.Insulin-like growth factors and their binding proteins: biological actions.Endocr Rev. 1995;16 (1): 3-34.
12. Pollak MN,Schernhammer ES,Hankinson SE.Insulin-like growth factors and neoplasia.Nat Rev Cancer. 2004;4 (7): 505-18.
13. Chan JM,Stampfer MJ,Ma J, et al.Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.J Natl Cancer Inst. 2002;94 (14): 1099-106.
14. Platz EA,Pollak MN,Leitzmann MF,Stampfer MJ,Willett WC,Giovannucci E.Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.Cancer Causes Control. 2005;16 (3): 255-62.
15. Stattin P,Rinaldi S,Biessy C,Stenman UH,Hallmans G,Kaaks R.High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.J Clin Oncol. 2004;22 (15): 3104-12.
16. Li L,Yu H,Schumacher F,Casey G,Witte JS.Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).Cancer Causes Control. 2003;14 (8): 721-6.
17. Wolk A,Mantzoros CS,Andersson SO, et al.Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.J Natl Cancer Inst. 1998;90 (12): 911-5.
18. Shi R,Berkel HJ,Yu H.Insulin-like growth factor-I and prostate cancer: a meta-analysis.Br J Cancer. 2001;85 (7): 991-6.
19. Renehan AG,Zwahlen M,Minder C,O'Dwyer ST,Shalet SM,Egger M.Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.Lancet. 2004;363 (9418): 1346-53.
20. Gelmann EP,Steadman DJ,Ma J, et al.Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function.Cancer Res. 2002;62 (9): 2654-9.
21. Muhlbradt E,Asatiani E,Ortner E,Wang A,Gelmann EP.NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.Cancer Res. 2009;69 (6): 2615-22.
22. Abdulkadir SA,Magee JA,Peters TJ, et al.Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia.Mol Cell Biol. 2002;22 (5): 1495-503.
23. Rhodes DR,Barrette TR,Rubin MA,Ghosh D,Chinnaiyan AM.Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.Cancer Res. 2002;62 (15): 4427-33.
24. Magee JA,Abdulkadir SA,Milbrandt J.Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation.Cancer Cell. 2003;3 (3): 273-83.
25. Magee JA,Araki T,Patil S, et al.Expression profiling reveals hepsin overexpression in prostate cancer.Cancer Res. 2001;61 (15): 5692-6.
26. Steadman DJ,Giuffrida D,Gelmann EP.DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1.Nucleic Acids Res. 2000;28 (12): 2389-95.
27. Carson JA,Fillmore RA,Schwartz RJ,Zimmer WE.The smooth muscle gamma-actin gene promoter is a molecular target for the mouse bagpipe homologue, mNkx3-1, and serum response factor.J Biol Chem. 2000;275 (50): 39061-72.
28. Ju JH,Maeng JS,Zemedkun M, et al.Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor.J Mol Biol. 2006;360 (5): 989-99.
29. Sutherland BW,Knoblaugh SE,Kaplan-Lefko PJ,Wang F,Holzenberger M,Greenberg NM.Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.Cancer Res. 2008;68 (9): 3495-504.
30. Kaplan-Lefko PJ,Sutherland BW,Evangelou AI, et al.Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.Oncogene. 2008;27 (20): 2868-76.
31. Ning Y,Schuller AG,Bradshaw S, et al.Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5.Mol Endocrinol. 2006;20 (9): 2173-86.
32. Wood TL,Rogler LE,Czick ME,Schuller AG,Pintar JE.Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene.Mol Endocrinol. 2000;14 (9): 1472-82.
33. Koistinen H,Paju A,Koistinen R, et al.Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3.Prostate. 2002;50 (2): 112-8.
34. Draisma G,Etzioni R,Tsodikov A, et al.Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.J Natl Cancer Inst. 2009;101 (6): 374-83.
35. Richiardi L,Fiano V,Vizzini L, et al.Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.J Clin Oncol. 2009;27 (19): 3161-8.
36. Giovannucci E,Liu Y,Platz EA,Stampfer MJ,Willett WC.Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.Int J Cancer. 2007;121 (7): 1571-8.
37. Benson DW,Silberbach GM,Kavanaugh-McHugh A, et al.Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways.J Clin Invest. 1999;104 (11): 1567-73.
38. Kasahara H,Lee B,Schott JJ, et al.Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease.J Clin Invest. 2000;106 (2): 299-308.
39. Song H,Zhang B,Watson MA,Humphrey PA,Lim H,Milbrandt J.Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.Oncogene. 2009;28 (37): 3307-19.